This diagnostic blind spot carries significant clinical implications, as IGH::CRLF2 rearrangements are enriched in Ph-like B-cell acute lymphoblastic leukemia (Ph-like B-ALL) and have been associated with high-risk disease features and poor clinical outcomes [6]. This evidence concerns the gene CRLF2 and acute lymphoblastic leukemia.